Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 01, 2006 (Vol. 26, No. 15)

NURSA: Nuclear Receptor Signaling Atlas

  • Excellently focused
  • Dull in Places
Looking at this website reminds me of the tremendous amount of progress we’ve made at the biological and computational level. Who would have thought 20 years ago that there would be a discipline of nuclear receptor signaling and that scientists worldwide would be able to access information about it from the comfort of their home computers? Well, that’s the way it is today, and who can’t say hooray to that? At the site, visitors will discover general information like meeting dates, as well as open access datasets, a nifty narrated/animated review of the topic, and an open access journal (Nuclear Receptor Signaling) serving the research community. Topic areas of the journal include Perspectives, Methods, Reviews, and Most Viewed. This is a dandy idea and a great service to the nuclear receptor community. Kudos!
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »